BLTE · Belite Bio, Inc
$162.80
-3.48 (-2.09%)
At close · Aug 14
Market Cap
$6.53B
Shares
40.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$162.80
Open$166.51
Day$159.00–167.00
52W close$61.81–190.30
Avg vol 30d181K
Short int1.1M · 2.8% float · 6.7d
Short vol57%
Last earningsJul 8, 2026
DataApr 2022–Aug 2026
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
+7%
above
RSI (14)
53
neutral
MACD trend
Positive
52-week position
79%
mid-range
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−14%
trailing
YTD return
+2%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $152 › 200d $154 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$2.9M over 90 days · 100% sells
Short interest
Falling
2.83% of float · ▼ -13.7% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
EPS growth
−96%
Y/Y
Free cash flow
$-37.1M
Balance sheet
$352.9M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
R&D-related activity costs
· next three years
$150M
Commercialization costs
· next three years
$200M – $250M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
79%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $152 › 200d $154 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$2.9M over 90 days · 100% sells
Short interest
Falling
2.83% of float · ▼ -13.7% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $62
Now $163 · 79%
Range high $190
vs 200-day avg +6%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLTE
this stock
Belite Bio, Inc
|
$6.53B | +1.8% | — | — | 2.8% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLTE | -0.2% | +8.5% | -14.0% | +2.6% | +1.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.6% | +4.0% | -27.8% | -1.3% | -12.1% |
Key facts
CIK
1889109
CUSIP
07782B104
13F (30d)
82 filings
81 filers
Visit website
Investor relations